ZULVAC 1+8 Ovis

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion / Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
IB/0021/G	This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	21/06/2019		SPC, Labelling and PL	The Agency accepted the group of variations to add an alternative supplier of packaging components and to correct translation errors in the product information. Additionally, the local representatives were deleted from the package leaflet. The product information was also updated in accordance with the latest version of the QRD template.
IG/0951	C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) in the safety database and/or major contractual arrangements for the fulfilment of PhV obligations, and/or change of the site undergoing PhV activities	05/07/2018	n/a		The Agency accepted the variation to update the current detailed description of the pharmacovigilance system (DDPS).
IG/0851	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	15/11/2017	n/a		The Agency accepted the variation to change the name of the secondary packaging site.
WS/1096	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.	13/07/2017	n/a		The Agency accepted a variation to amend the conduct of the batch potency test for the Zulvac BTV range of vaccines.

[1] Notifications are issued for type I variations (unless part of a group including a type II variation or higher procedure or a worksharing application). Opinions are issued for all other procedures.
[2] A CD is issued for procedures that affect the terms of the marketing authorisation (e.g. SPC, Annex II, Labelling, PL). The CD is issued within 2 months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within 1 year for other procedures.
[3] SPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Temporary visiting address Spark building ● Orlyplein 24 ● 1043 DP Amsterdam ● The Netherlands
For deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

	B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)				
WS/1039	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.d - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New manufacturer of material for which an assessment is required of viral safety and/or TSE risk	12/04/2017	n/a		The Agency accepted the variation to replace the currently approved supplier of a starting material.
IG/0747	C.II.6.a - Changes to the labelling or the PL which are not connected with the SPC - Administrative information concerning the holder's representative	23/03/2017	27/03/2018	SPC, Labelling and PL	The Agency accepted the variation to update the list of local representatives in the product information.
WS/1040	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	19/01/2017	n/a		The Agency accepted the variation to update a test procedure.
R/0014	Renewal of the marketing authorisation.	06/11/2015	07/01/2016	SPC, Annex II, Labelling and PL	The European Commission renewed the marketing authorisation for ZULVAC 1+8 Ovis.
IG/0538	C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV and/or QPPV contact details and/or back-up procedure	01/04/2015	n/a		The Agency accepted the variation to change the QPPV.
WS/0597	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	06/11/2014	n/a		The Agency accepted a variation to make changes to the manufacturing process.
IG/0359	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	25/10/2013	n/a		The Agency accepted the variation to add a manufacturing site for secondary packaging of the finished product.
IG/0330/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites	05/09/2013	16/09/2014	SPC, Annex II, Labelling and PL	The Agency accepted a group of variations to change the name of the manufacturer of the active substance, finished product and batch release site

	(excluding manufacturer for batch release)				
IG/0328	C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV and/or QPPV contact details and/or back-up procedure	05/09/2013	n/a		The Agency accepted the variation to update the contact details of the QPPV.
S/0006		16/05/2013	26/07/2013	SPC, Annex II, Labelling and PL	The CVMP reviewed the specific obligations and concluded that, overall, the evidence continues to support a favourable benefit-risk profile for ZULVAC 1+ 8 Ovis. Since all specific obligations stated in Annex II of the CVMP opinion dated 11 November 2009 have been fulfilled, there are no remaining grounds for the marketing authorisation to remain under exceptional circumstances.
WS/0377/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.III.2.a.2 - Change of specification(s) of a former non Pharmacopoeial substance to comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material	13/06/2013	n/a		The Agency accepted a group of variations to make changes concerning the manufacture of the active substance.
T/0008	Transfer of Marketing Authorisation	26/04/2013	27/05/2013	SPC, Labelling and PL	The European Commission amended the decision granting the marketing authorisation to transfer the marketing authorisation from 'Pfizer Ltd' to 'Zoetis Belgium SA'.
S/0005		12/07/2012	n/a		The CVMP reviewed the specific obligations and concluded that, overall, the evidence continues to support a favourable benefit-risk profile for ZULVAC 1+ 8 Ovis. Full approval will, however, remain conditional on the fulfilment of the outstanding specific obligations as outlined in Annex II E of the opinion.
WS/0230	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products	14/06/2012	14/06/2012		The Agency accepted a variation for a change to the dimensions of stoppers for 250 ml and 500 ml presentations.
IB/0001	C.II.6 - Changes to the labelling or the package leaflet which are not connected with the SPC	20/05/2011	19/09/2011	PL	The Agency accepted a variation to add the list of local representatives to the package leaflet.
IG/0006/G	This was an application for a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS,	30/06/2011	19/09/2011	Annex II and PL	The Agency accepted a group of variations to change the name of the active substance manufacturer, the name of the batch release site and the name of the finished product manufacturer.

	starting material, reagent or intermediate used in the manufacture of the AS A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release)				
IG/0005/G	This was an application for a group of variations. C.I.9.g - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the site undertaking pharmacovigilance activities	05/08/2011	05/08/2011		The Agency accepted a group of variations to change the location of the Qualified Person for Pharmacovigilance.